Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
20
Not yet recruiting, industry sponsors, Ophthalmology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed279
20 trials
Showing 1 to 20, recently updated first.
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®Not yet recruiting
Laboratorios Sophia S.A de C.V.Industry
NCT06375343 · 32 participants (planned) · Start Jul 30, 2027 · Primary completion Mar 30, 2028
Drug: PRO-240; Optive® · For: Dry Eye Disease; Dry Eye Sensation; Ocular Surface Disease
- R-2487 in Patients With Sjogren's Syndrome (SjD)Not yet recruiting
Rise Therapeutics LLCIndustry
NCT06297213 · 36 participants (planned) · Start Nov 1, 2026 · Primary completion Aug 30, 2029
Drug: R-2487 · For: Sjogren's Syndrome; Sjögren; Sjögren Syndrome, Unspecified
Sites: Baltimore, Maryland; Ann Arbor, Michigan
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT07906145 · 76 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: QLS2416 Injection · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis (RA); Primary Sjögren's Syndrome (pSS) and 1 more
- A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases.Not yet recruiting
Guangdong ProCapZoom Biosciences Co., Ltd.Industry
NCT07902687 · 20 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 30, 2028
Drug: MSCohi-O lens · For: Keratitis; Autoimmunity; Dry Eye Disease (DED)
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07873931 · 60 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 20, 2032
Drug: BMS-986553 · For: Systemic Lupus Erythematosus; Sjögren's Disease; Rheumatoid Arthritis and 3 more
Sites: Newport Beach, California; Worcester, Massachusetts; Ann Arbor, Michigan · 23 sites in all
Filamon LTDIndustry
NCT07766473 · 24 participants (planned) · Start Sep 2026 · Primary completion Mar 2027
Drug: BETA-TT8 ophthalmic gel 3.8% w/v · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Gosford, Australia; Sydney, Australia; Westmead, Australia · 4 sites in all
- A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein OcclusionNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07817615 · 60 participants (planned) · Start Sep 2026 · Primary completion Jun 2028
Drug: GenSci148 Injection · For: Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Sites: Shanghai, China
- A First-in-human Trial of SZN-8141 in Diabetic Macular EdemaNot yet recruiting
Surrozen Operating, Inc.Industry
NCT07817121 · 9 participants (planned) · Start Oct 30, 2026 · Primary completion Aug 31, 2027
Drug: SZN-8141 for Injection · For: Diabetic Macular Edema (DME)
- Evaluation of PAN-90806 Eye Drops in Healthy SubjectsNot yet recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT07764965 · 20 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 30, 2026
Drug: PAN-90806 Ophthalmic Solution; Vehicle Ophthalmic Solution · For: Wet Age Related Macular Degeneration; Neovascular (Wet) Age-Related Macular Degeneration
Augelux TherapeuticsIndustry
NCT07602127 · 24 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 30, 2028
Drug: AGX-08-L; AGX-08-H · For: Geographic Atrophy
- CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune DiseasesNot yet recruiting
Nanjing Bioheng Biotech Co., Ltd.Industry
NCT07596680 · 30 participants (planned) · Start Sep 1, 2026 · Primary completion Apr 30, 2028
Drug: RD06-05 CAR-T Cell Injection · For: SLE - Systemic Lupus Erythematosus; Systemic Sclerosis; ANCA Associated Vasculitis and 2 more
Sites: Shanghai, China
SpyGlass Pharma, Inc.Industry
NCT07641296 · 24 participants (planned) · Start Jul 31, 2026 · Primary completion Feb 28, 2027
Drug: BIM-DRS Low Dose; BIM-DRS High Dose · For: Glaucoma; Ocular Hypertension
Nanjing Reju Therapeutics Co., LtdIndustry
NCT07521748 · 24 participants (planned) · Start Apr 2026 · Primary completion Dec 2026
Drug: RC017 Ophthalmic Ointment; RC017 Ophthalmic Ointment placebo · For: Dry Eye
Laboratorios Sophia S.A de C.V.Industry
NCT07429474 · 60 participants (planned) · Start Mar 1, 2026 · Primary completion Dec 15, 2026
Drug: PRO-169 · For: Immunogenicity; Anti-drug Antibodies (ADAs)
Sites: Coyoacán, Mexico
- Exosomes in Patients With Ocular Involvement of Sjögren's SyndromeNot yet recruiting
Guangdong ProCapZoom Biosciences Co., Ltd.Industry
NCT07192666 · 12 participants (planned) · Start Sep 15, 2025 · Primary completion Sep 30, 2026
Drug: Exosome Preparation · For: Sjögren's Syndrome
- MSCohi-O Lenses for Ocular Involvement in Sjögren's SyndromeNot yet recruiting
Guangdong ProCapZoom Biosciences Co., Ltd.Industry
NCT07185139 · 12 participants (planned) · Start Sep 12, 2025 · Primary completion Aug 30, 2026
Drug: MSCohi-O Lenses · For: Sjögren's Syndrome
- Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMDNot yet recruiting
Guangzhou Jiayin Biotech LtdIndustry
NCT07178249 · 60 participants (planned) · Start Oct 16, 2025 · Primary completion Feb 28, 2028
Drug: EXG202 injection · For: Wet Age-related Macular Degeneration
- To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)Not yet recruiting
Guangzhou Jiayin Biotech LtdIndustry
NCT06888492 · 8 participants (planned) · Start Mar 28, 2025 · Primary completion Apr 25, 2026
Drug: EXG202 · For: Wet Age-related Macular Degeneration (wAMD); Wet Age-related Macular Degeneration
Sites: Xingtai, China; Yiwu, China
- Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.Not yet recruiting
Laboratorios Sophia S.A de C.V.Industry
NCT06379685 · 32 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2026
Drug: PRO-190; Systane Ultra® · For: Dry Eye; Dry Eyes Chronic; Dry Eye Syndromes
- Study of JMKX003948 Ophthalmic Suspension in Healthy ParticipantsNot yet recruiting
JemincareIndustry
NCT06832657 · 40 participants (planned) · Start Feb 2025 · Primary completion Dec 2025
Drug: JMKX003948 Ophthalmic Suspension; Placebo · For: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.